Quest PharmaTech Inc. (CVE:QPT – Get Free Report) hit a new 52-week high on Tuesday . The company traded as high as C$0.04 and last traded at C$0.04, with a volume of 688986 shares traded. The stock had previously closed at C$0.03.
Quest PharmaTech Trading Up 33.3 %
The company has a debt-to-equity ratio of 4.35, a quick ratio of 0.52 and a current ratio of 0.40. The firm has a market cap of C$6.77 million, a PE ratio of -2.00 and a beta of 0.14. The stock has a 50-day simple moving average of C$0.03 and a two-hundred day simple moving average of C$0.03.
Quest PharmaTech Company Profile
Quest PharmaTech Inc, a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer.
Featured Stories
- Five stocks we like better than Quest PharmaTech
- 3 Stocks to Consider Buying in October
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- There Are Different Types of Stock To Invest In
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- Roth IRA Calculator: Calculate Your Potential Returns
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Quest PharmaTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest PharmaTech and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.PNG?v=20210211152200&h=45&w=95&zc=2){kind=logo}
